Browsing by Author "Ashok Kumar Datusalia"

Now showing 1 - 2 of 2

Artificial intelligence and machine learning disciplines with the potential to improve the nanotoxicology and nanomedicine fields: a comprehensive review
(Springer Science and Business Media Deutschland GmbH, 2023) Ajay Vikram Singh; Mansi Varma; Peter Laux; Sunil Choudhary; Ashok Kumar Datusalia; Neha Gupta; Andreas Luch; Anusha Gandhi; Pranav Kulkarni; Banashree Nath
The use of nanomaterials in medicine depends largely on nanotoxicological evaluation in order to ensure safe application on living organisms. Artificial intelligence (AI) and machine learning (MI) can be used to analyze and interpret large amounts of data in the field of toxicology, such as data from toxicological databases and high-content image-based screening data. Physiologically based pharmacokinetic (PBPK) models and nano-quantitative structure–activity relationship (QSAR) models can be used to predict the behavior and toxic effects of nanomaterials, respectively. PBPK and Nano-QSAR are prominent ML tool for harmful event analysis that is used to understand the mechanisms by which chemical compounds can cause toxic effects, while toxicogenomics is the study of the genetic basis of toxic responses in living organisms. Despite the potential of these methods, there are still many challenges and uncertainties that need to be addressed in the field. In this review, we provide an overview of artificial intelligence (AI) and machine learning (ML) techniques in nanomedicine and nanotoxicology to better understand the potential toxic effects of these materials at the nanoscale. © 2023, The Author(s).
Novel molecular insights into the role of CRH type 1 receptor in the pathophysiology of depression
(Elsevier Inc., 2025) Patel Parthkumar Rakeshkumar; Sumadhura Bommaraju; Ashok Kumar Datusalia; Prasanta Kumar Nayak
Depression is a debilitating mental health condition marked by persistent sadness, loss of pleasure, and suicidal thoughts. The continuous rise in cases of depression signifies the lack of efficient treatment options and therapeutic targets. Corticotropin-releasing hormone (CRH) is a member of the neuropeptide family and is a robust component of the hypothalamic–pituitary–adrenal (HPA) axis dysregulation in depression. Several studies have highlighted the significant role of corticotropin-releasing hormone receptor type 1 (CRHR1) in the development of depressive symptoms. CRHR1, a member of the G-protein-coupled receptor (GPCR) superfamily, is widely distributed throughout the mammalian brain and plays a dynamic role in brain function, notably interacting with neurotransmitters such as glutamate, serotonin, and dopamine, which are crucial in brain functioning. Furthermore, genetic alterations such as polymorphism and epigenetic modification in the Crhr1 gene increase the risk of depression. Additionally, we discussed the role of CRHR1 in novel mechanisms such as synaptic plasticity, neuroinflammation, autophagy, and gut dysbiosis, and its implications in depression. This article compiles and discusses emerging evidence regarding the role of CRHR1 in these mechanisms, which are central to the pathophysiology of depression. Evidence suggests that the CRHR1 may play an even more crucial role than CRH in the manifestation of depressive symptoms; we also examined this aspect briefly. In conclusion, these findings underscore the importance of CRHR1 in the neurobiological mechanisms underlying depression, suggesting that targeting this receptor could be a potential therapeutic avenue for treating mood disorders. © 2025 Elsevier Inc.